Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine combination with antitumor activity

An anti-tumor activity, anti-tumor drug technology, applied in the field of a pharmaceutical composition, can solve the problem that DMXAA is unlikely to be clinically useful

Inactive Publication Date: 2009-01-07
沈阳斯佳科技发展有限公司
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, with studies showing rapid tumor regeneration from surviving cells in the well-perfused periphery, it is clear that DMXAA is unlikely to have clinical utility as a single agent or drug

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine combination with antitumor activity
  • Medicine combination with antitumor activity
  • Medicine combination with antitumor activity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Example 1 Synergistic Combination of DMXAA and Pingyangmycin

[0058] Material:

[0059] Cell lines: human lung cancer A549 cells and liver cancer SMMC-7721 cells

[0060] Preparation of test drugs: D XAA was dissolved with 5% sodium bicarbonate before use, and then made into the required concentration with RPMI1640 culture solution; Pingyangmycin (PYM) was dissolved with normal saline before use, and then made with RPMI1640 culture solution concentration.

[0061] Cell culture:

[0062] Inoculate human lung cancer A549 cells and liver cancer SMMC-7721 cells into sterile culture flasks, add appropriate amount of RPMI1640 culture medium, and incubate at 37°C, 5% CO 2 cultured in an incubator with saturated humidity. The cells grow purely adherent and are passaged every 2-3 days. Digest with 3g / L trypsin for 1min during subculture, pipette with culture medium to make cell suspension, and inoculate according to the required concentration.

[0063] method:

[0064] ...

Embodiment 2

[0086] Example 2 Synergistic combination of DMXAA and actinomycin D

[0087] Material:

[0088] Cell lines: human lung cancer A549 cells and liver cancer SMMC-7721 cells

[0089] Preparation of test drugs: DMXAA was dissolved with 5% sodium bicarbonate before use, and then made into the required concentration with RPMI1640 culture solution; actinomycin D was dissolved in normal saline before use, and then made into the required concentration with RPMI1640 culture solution.

[0090] Cell culture:

[0091] Inoculate human lung cancer A549 cells and liver cancer SMMC-7721 cells into sterile culture flasks, add appropriate amount of RPMI1640 culture medium, and incubate at 37°C, 5% CO 2 cultured in an incubator with saturated humidity. The cells grow purely adherent and are passaged every 2-3 days. Digest with 3g / L trypsin for 1min during subculture, pipette with culture medium to make cell suspension, and inoculate according to the required concentration.

[0092] method: ...

Embodiment 3

[0115] Example 3 Synergistic combination of DMXAA and mitomycin (MMC)

[0116] Material:

[0117] Cell lines: human lung cancer A549 cells and liver cancer SMMC-7721 cells

[0118] Preparation of test drugs: DMXAA was dissolved with 5% sodium bicarbonate before use, and then made into the required concentration with RPMI1640 culture solution; mitomycin (MMC) was dissolved with normal saline before use, and then made into the required concentration with RPMI1640 culture solution. concentration.

[0119] Cell culture:

[0120] Inoculate human lung cancer A549 cells and liver cancer SMMC-7721 cells into sterile culture flasks, add appropriate amount of RPMI1640 culture medium, and incubate at 37°C, 5% CO 2 cultured in an incubator with saturated humidity. The cells grow purely adherent and are passaged every 2-3 days. Digest with 3g / L trypsin for 1min during subculture, pipette with culture medium to make cell suspension, and inoculate according to the required concentrati...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition, particularly to a pharmaceutical composition with antitumor activity. The pharmaceutical composition with antitumor activity comprises 5,6-dimethylxanthenone-4-acetic acid (DMXAA) or an pharmaceutically acceptable salt or ester thereof and one drug component selected from glycopeptide antibiotics, actinomycins, mitomycins, glucoside antibiotics, Colchicum alkaloid, elemenes, aromatic enzyme inhibitors, LH-RH receptor antagonists, animal antitumor drugs and somatostatin analogues. The synergic composition has better antitumor activity. More specifically, the invention provides an application of the composition in treating tumors.

Description

technical field [0001] The present invention relates to a pharmaceutical composition, in particular to a compound 5,6-dimethylxanthone-4-acetic acid (DMXAA) or a pharmaceutically acceptable salt or ester thereof and a compound selected from glycopeptide antibiotics, radioactive Mitomycins, mitomycins, glycoside antibiotics, colchicine alkaloids, elemenes, aromatase inhibitors, LH-RH receptor antagonists, animal antineoplastic agents, or somatostatin-like The synergistic combination of any one of the drugs of the drug has stronger antitumor activity. Background technique [0002] Tumor growth depends on the formation of the vascular network inside the tumor. Under the promotion of vascular endothelial growth factor released by cancer cells and related macrophages, a large number of new blood vessels are formed, cancer cells continue to proliferate, oxygen and glucose are consumed in large quantities, and acidic metabolites accumulate. Stimulate the formation of new blood ves...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/352A61K45/00A61P35/00A61K38/14A61K38/08A61K31/407
Inventor 王光郑剑峰李莉孟凡英
Owner 沈阳斯佳科技发展有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com